The South San Francisco-based biotech says that Pfizer $PFE notified them yesterday that they are dropping out of the Probody deal, discarding its latest two targets after dumping the first on EGFR and never going after the fourth. The deal, which started out with a $25 million upfront payment and a large $610 million package of milestones, had helped validate CytomX’s platform tech on armed antibodies. Pfizer was looking for safer versions of Erbitux and Vectibix.
CytomX scored $60 million in upfront cash when Amgen signed up for a $1.5 billion deal last fall. And that came after Bristol-Myers Squibb forked over $200 million in cash to get the biotech focused on a safer, better CTLA-4 to eventually succeed Yervoy.
Amgen $AMGN jumped in for a T-cell engaging bispecific targeting the Epidermal Growth Factor Receptor (EGFR), a high-value target expressed on multiple cancer types. They’re building on the biotech’s preclinical work on an EGFRxCD3 program.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,300+ biopharma pros who read Endpoints News by email every day.Free Subscription